ClinicalTrials.gg
CompletedNCT06578949Updated Jun 5, 2026Results posted

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 3 interventional study of Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria and PNH, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca — 3 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · AstraZeneca.

Enrollment
14th of 23
18 · median 26
Started
2024
with 1 other
Phase 3
12 of 35
1 open now
Registered
32nd of 35
by date

Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 14th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2024, is one of 12 in phase 3, and was the 32nd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
  • PNH

Keywords

  • Paroxysmal Nocturnal Hemoglobinuria
  • PNH
  • Ravulizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult C5 inhibitor naive PNH patients (age>=18), which is confirmed by flow cytometry evaluation.
  • Must be vaccinated againast N meningitidis.

Exclusion criteria

Exclusion Criteria

  • Meningitidis infection or unresolved meningococcal disease
  • History of bone marrow transplantation
  • Other significant systemic diseases that might have impact on efficacy and safety assessment
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Ravulizumab

    During the Primary Treatment Period, participants will receive a weight-based loading dose of ravulizumab on Day 1 followed by weight-based maintenance dose of ravulizumab on Day 15 and once every 8 weeks (q8w) thereafter for a total of 26 weeks. On Day 183, all participants will enter a 32-week Extension Treatment Period and receive ravulizumab. Beginning on Day 183, participants will receive a maintenance dose of ravulizumab q8w for an additional 32 weeks.

    Drug: Ravulizumab

Interventions

  • Ravulizumab will be administered by intravenous (IV) infusion.

    Also known as: ALXN1210

06

What researchers measure

Primary outcomes

  1. Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)

    LDH is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicated reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first dose of study drug. The percent change in LDH was analyzed using a mixed-effect model for repeated measures (MMRM) with the fixed categorical effect of visit, fixed continuous effect of the LDH baseline value as covariates, and participant as random effect.

    Time frame: Baseline, Day 183 (Week 26)

Secondary outcomes

  1. Percentage of Participants Achieving LDH <1.5 * Upper Limit of Normal (ULN) at Day 183 (Week 26)

    LDH is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicated reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first dose of study drug.

    Time frame: Day 183 (Week 26)

  2. Percentage of Participants Achieving Transfusion Avoidance Through Day 183 (Week 26)

    Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 grams (g)/deciliter (dL) with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through Day 183.

    Time frame: Day 183 (Week 26)

  3. Percentage of Participants Experiencing Breakthrough Hemolysis Through Day 183 (Week 26)

    Breakthrough hemolysis was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia \[hemoglobin \<10 g/dL\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the ULN.

    Time frame: Day 183 (Week 26)

  4. Change in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) Score From Baseline to Day 183 (Week 26)

    The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with a higher score indicating better quality of life. Analysis was using a mixed-effect model for repeated measures (MMRM) with the fixed categorical effect of visit, fixed continuous effect of the baseline value of FACIT-Fatigue score as covariates, and participant as random effect.

    Time frame: Baseline, Day 183 (Week 26)

  5. Change in Hemoglobin (Hgb) From Baseline to Day 183 (Week 26)

    Analysis was performed using MMRM with the fixed categorical effect of visit, fixed continuous effect of the Hgb baseline value as covariates, and participant as random effect.

    Time frame: Baseline, Day 183 (Week 26)

07

Results

Posted Jun 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneRavulizumab
Started18
Received at least 1 dose of study drug18
Completed18
Not completed0

Outcome measures

PrimaryPercentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)

LDH is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicated reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first dose of study drug. The percent change in LDH was analyzed using a mixed-effect model for repeated measures (MMRM) with the fixed categorical effect of visit, fixed continuous effect of the LDH baseline value as covariates, and participant as random effect.

Time frame:
Baseline, Day 183 (Week 26)
Reported as:
Least squares mean · percent change
Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)
percent changeRavulizumab
Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)-81.3 (-84.2 to -78.3)
Statistical analysis
  • Ravulizumab · Mixed Models Analysis · p = < 0.001
SecondaryPercentage of Participants Achieving LDH <1.5 * Upper Limit of Normal (ULN) at Day 183 (Week 26)

LDH is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicated reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first dose of study drug.

Time frame:
Day 183 (Week 26)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving LDH <1.5 * Upper Limit of Normal (ULN) at Day 183 (Week 26)
percentage of participantsRavulizumab
Percentage of Participants Achieving LDH <1.5 * Upper Limit of Normal (ULN) at Day 183 (Week 26)94.1 (71.3 to 99.9)
SecondaryPercentage of Participants Achieving Transfusion Avoidance Through Day 183 (Week 26)

Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 grams (g)/deciliter (dL) with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through Day 183.

Time frame:
Day 183 (Week 26)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Transfusion Avoidance Through Day 183 (Week 26)
percentage of participantsRavulizumab
Percentage of Participants Achieving Transfusion Avoidance Through Day 183 (Week 26)94.4 (72.7 to 99.9)
SecondaryPercentage of Participants Experiencing Breakthrough Hemolysis Through Day 183 (Week 26)

Breakthrough hemolysis was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia \[hemoglobin \<10 g/dL\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the ULN.

Time frame:
Day 183 (Week 26)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Breakthrough Hemolysis Through Day 183 (Week 26)
percentage of participantsRavulizumab
Percentage of Participants Experiencing Breakthrough Hemolysis Through Day 183 (Week 26)0 (0.0 to 18.5)
SecondaryChange in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) Score From Baseline to Day 183 (Week 26)

The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with a higher score indicating better quality of life. Analysis was using a mixed-effect model for repeated measures (MMRM) with the fixed categorical effect of visit, fixed continuous effect of the baseline value of FACIT-Fatigue score as covariates, and participant as random effect.

Time frame:
Baseline, Day 183 (Week 26)
Reported as:
Least squares mean · units on a scale
Change in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) Score From Baseline to Day 183 (Week 26)
units on a scaleRavulizumab
Change in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) Score From Baseline to Day 183 (Week 26)4.5 (1.3 to 7.7)
SecondaryChange in Hemoglobin (Hgb) From Baseline to Day 183 (Week 26)

Analysis was performed using MMRM with the fixed categorical effect of visit, fixed continuous effect of the Hgb baseline value as covariates, and participant as random effect.

Time frame:
Baseline, Day 183 (Week 26)
Reported as:
Least squares mean · g/liter (L)
Change in Hemoglobin (Hgb) From Baseline to Day 183 (Week 26)
g/liter (L)Ravulizumab
Change in Hemoglobin (Hgb) From Baseline to Day 183 (Week 26)26.6 (13.8 to 39.3)

Adverse events

Collected over Baseline up to Week 26. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ravulizumab0/18 (0%)2/18 (11.1%)16/18 (88.9%)
Most frequent serious events
Most frequent serious events
EventRavulizumab
Liver injuryHepatobiliary disorders1/18
PyrexiaGeneral disorders1/18
Most frequent other events
Showing 10 of 30
Most frequent other events
EventRavulizumab
HeadacheNervous system disorders7/18
Upper respiratory tract infectionInfections and infestations4/18
DiarrhoeaGastrointestinal disorders3/18
Decreased appetiteMetabolism and nutrition disorders2/18
HypokalaemiaMetabolism and nutrition disorders2/18
DizzinessNervous system disorders2/18
InfluenzaInfections and infestations1/18
PeriodontitisInfections and infestations1/18
SinusitisInfections and infestations1/18
Tinea pedisInfections and infestations1/18

Baseline characteristics

Full Analysis Set (FAS) included all enrolled participants who received at least 1 dose (full or partial) of the study intervention.

Age, Continuous
Age, Continuous(years)Ravulizumab
Mean42.8 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Ravulizumab
Female3
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ravulizumab
Hispanic or Latino0
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ravulizumab
American Indian or Alaska Native0
Asian18
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

8 sites
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Nantong, 226001, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Tianjin, 300020, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Wuhan, 430022, China
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2025, 7 months.

Results were first posted in Jun 2026, 1 year after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 7 months is below that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Oct 10, 2024
Primary completionActual
May 15, 2025
CompletionActual
Dec 22, 2025
Results first posted
Jun 5, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06578949
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Oct 10, 2024
Primary completion
May 15, 2025
Completion
Dec 22, 2025
Results posted
Jun 5, 2026
Last update
Jun 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion